JP2008525409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525409A5 JP2008525409A5 JP2007547651A JP2007547651A JP2008525409A5 JP 2008525409 A5 JP2008525409 A5 JP 2008525409A5 JP 2007547651 A JP2007547651 A JP 2007547651A JP 2007547651 A JP2007547651 A JP 2007547651A JP 2008525409 A5 JP2008525409 A5 JP 2008525409A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- och
- nme
- ome
- ipr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 65
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 51
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 41
- 125000001424 substituent group Chemical group 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- 125000006413 ring segment Chemical group 0.000 claims 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 9
- -1 hydroxyimino Chemical group 0.000 claims 9
- 125000001544 thienyl group Chemical group 0.000 claims 9
- 125000002541 furyl group Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims 7
- 125000005488 carboaryl group Chemical group 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 5
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 5
- 125000000335 thiazolyl group Chemical group 0.000 claims 5
- 150000003573 thiols Chemical class 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 125000002785 azepinyl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 150000003456 sulfonamides Chemical class 0.000 claims 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 3
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 3
- 150000003568 thioethers Chemical class 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 230000001668 ameliorated effect Effects 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 2
- 235000021317 phosphate Nutrition 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63789204P | 2004-12-22 | 2004-12-22 | |
| GBGB0428082.2A GB0428082D0 (en) | 2004-12-22 | 2004-12-22 | Therapeutic compounds |
| PCT/GB2005/005011 WO2006067466A2 (en) | 2004-12-22 | 2005-12-22 | Pyrazines and pyridines and derivatives thereof as therapeutic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008525409A JP2008525409A (ja) | 2008-07-17 |
| JP2008525409A5 true JP2008525409A5 (enExample) | 2009-02-12 |
Family
ID=34113050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547651A Withdrawn JP2008525409A (ja) | 2004-12-22 | 2005-12-22 | 治療用化合物としてのピラジンおよびピリジンならびにその誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7737152B2 (enExample) |
| EP (1) | EP1831184B1 (enExample) |
| JP (1) | JP2008525409A (enExample) |
| AT (1) | ATE497951T1 (enExample) |
| AU (1) | AU2005317890A1 (enExample) |
| CA (1) | CA2591208A1 (enExample) |
| DE (1) | DE602005026321D1 (enExample) |
| GB (1) | GB0428082D0 (enExample) |
| NZ (1) | NZ556125A (enExample) |
| WO (1) | WO2006067466A2 (enExample) |
| ZA (1) | ZA200705979B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005027A (es) * | 2001-11-28 | 2004-08-11 | Btg Int Ltd | Preventivos o remedios para la enfermedad de alzheimer, o inhibidores de la formacion de fibrillas de proteina amiloide, que incluyen un compuesto heteroarilo que contiene nitrogeno. |
| WO2006099075A2 (en) * | 2005-03-10 | 2006-09-21 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| US20080039450A1 (en) * | 2006-06-22 | 2008-02-14 | Jensen Annika J | Compounds |
| JP2008081492A (ja) | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| EP1992344A1 (en) * | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| WO2009037247A1 (en) * | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| AU2014253528B2 (en) * | 2007-12-19 | 2016-07-21 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| AU2008337286B2 (en) * | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| EP2252597B1 (en) | 2008-02-01 | 2014-03-19 | Akinion Pharmaceuticals AB | Pyrazine derivatives and their use as protein kinase inhibitors |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| KR101789129B1 (ko) | 2010-06-30 | 2017-11-20 | 후지필름 가부시키가이샤 | 신규 니코틴아미드 유도체 또는 그 염 |
| WO2012070024A1 (en) * | 2010-11-28 | 2012-05-31 | Metasignal Therapeutics Inc. | Carbonic anhydrase inhibitors with antimetastatic activity |
| WO2012122444A1 (en) | 2011-03-10 | 2012-09-13 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| US10713634B1 (en) | 2011-05-18 | 2020-07-14 | Stamps.Com Inc. | Systems and methods using mobile communication handsets for providing postage |
| JP6321673B2 (ja) * | 2012-12-20 | 2018-05-09 | ルゥ チーン−ビン | 放射線と組み合わせて使用するための放射線増感剤化合物 |
| EP3578176A1 (en) * | 2013-10-08 | 2019-12-11 | Lu, Qing-Bin | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EA202092442A3 (ru) | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| WO2018172984A1 (en) | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
| CN111499613B (zh) * | 2019-01-31 | 2023-05-12 | 浙江海正药业股份有限公司 | N-甲酰胺衍生物、其制备方法及其在医药上的用途 |
| WO2020236524A1 (en) * | 2019-05-17 | 2020-11-26 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| WO2020252229A2 (en) * | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CN115443267B (zh) | 2020-04-28 | 2025-09-05 | 巴斯夫欧洲公司 | 杀害虫化合物 |
| CA3184471A1 (en) * | 2020-05-27 | 2021-12-02 | The Penn State Research Foundation | Antibacterial compounds |
| JP2023529867A (ja) | 2020-06-05 | 2023-07-12 | キネート バイオファーマ インク． | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
| WO2022098808A1 (en) * | 2020-11-05 | 2022-05-12 | Aria Pharmaceuticals, Inc. | Therapeutic agents for treating hepatocellular carcinoma |
| CN116272897B (zh) * | 2023-02-27 | 2024-08-27 | 中国检验检疫科学研究院 | 富集香豆素类化合物的磁性纳米粒及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| ATE294236T1 (de) | 1994-09-22 | 2005-05-15 | Licentia Ltd | Promotor der tie rezeptor protein kinase |
| US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| DE69630214T2 (de) | 1995-03-10 | 2004-07-15 | Berlex Laboratories, Inc., Richmond | Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| ES2153337T3 (es) | 1997-05-23 | 2008-11-01 | Bayer Pharmaceuticals Corporation | Inhibidores de la quinasa raf. |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| BR0013899A (pt) * | 1999-09-10 | 2003-07-08 | Merck & Co Inc | Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral |
| AU9458401A (en) | 2000-09-20 | 2002-04-02 | Ortho Mcneil Pharm Inc | Pyrazine derivatives as modulators of tyrosine kinases |
| EP1363702A4 (en) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
| EP1578722A4 (en) | 2001-10-12 | 2006-09-06 | Irm Llc | KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF |
| MXPA04004178A (es) | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta. |
| WO2003056036A2 (en) | 2001-12-21 | 2003-07-10 | The Wellcome Trust | Genes |
| NZ537155A (en) | 2002-05-23 | 2006-09-29 | Cytopia Pty Ltd | Protein kinase inhibitors |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| EP1644365A2 (en) * | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
-
2004
- 2004-12-22 GB GBGB0428082.2A patent/GB0428082D0/en not_active Ceased
-
2005
- 2005-12-22 NZ NZ556125A patent/NZ556125A/en unknown
- 2005-12-22 AU AU2005317890A patent/AU2005317890A1/en not_active Abandoned
- 2005-12-22 AT AT05821735T patent/ATE497951T1/de not_active IP Right Cessation
- 2005-12-22 DE DE602005026321T patent/DE602005026321D1/de not_active Expired - Lifetime
- 2005-12-22 WO PCT/GB2005/005011 patent/WO2006067466A2/en not_active Ceased
- 2005-12-22 US US11/722,612 patent/US7737152B2/en not_active Expired - Fee Related
- 2005-12-22 CA CA002591208A patent/CA2591208A1/en not_active Abandoned
- 2005-12-22 JP JP2007547651A patent/JP2008525409A/ja not_active Withdrawn
- 2005-12-22 ZA ZA200705979A patent/ZA200705979B/xx unknown
- 2005-12-22 EP EP05821735A patent/EP1831184B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2442778C9 (ru) | Новые соединения, действующие как ингибиторы erk | |
| JP2004511462A5 (enExample) | ||
| JP2015535831A5 (enExample) | ||
| JP2005517675A5 (enExample) | ||
| JP2020503340A5 (enExample) | ||
| RU2009130599A (ru) | Лекарственные препараты для лечения рака | |
| UY38742A (es) | Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida | |
| EP4473980A3 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
| ES2173154T3 (es) | Compuestos de naftilo, intermedios, procedimientos y composiciones de los mismos. | |
| JP2005523922A5 (enExample) | ||
| JP2019514955A5 (enExample) | ||
| RU2006139005A (ru) | Применение производных 9н-пурин-2, 6-диамина для лечения пролиферативных заболеваний и новые производные 9н-пурин-2, 6-диамина | |
| JP2019515643A5 (enExample) | ||
| JP2005511556A5 (enExample) | ||
| JP2025513882A5 (enExample) | ||
| JP2007525494A5 (enExample) | ||
| AU2007290490A1 (en) | Combination with bis(thiohydrazide amides) for treating cancer | |
| JP2014502599A5 (enExample) | ||
| CN116139125A (zh) | 联合治疗 | |
| RU2007105233A (ru) | Производные порфирина и их применение в фотонно-активационной терапии | |
| JP2024502175A5 (enExample) | ||
| JP2023509944A5 (enExample) | ||
| WO2017190107A1 (en) | Sigma receptor binders | |
| CA2321149A1 (en) | Antitumor agents | |
| CA2519110A1 (fr) | Derives du benzenesulfonamide, leur procede de preparation et leur utilisation dans le traitement de la douleur |